Arcturus Therapeutics Holdings Inc. Common Stock (ARCT)
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on developing next-generation RNA medicines and vaccines. Established with the aim of transforming the treatment of rare and infectious diseases, Arcturus leverages its proprietary LUNAR lipid-mediated delivery platform to enhance the efficacy of RNA-based therapeutics. The company primarily engages in research, development, and commercialization efforts within the fields of immunology, neurology, and genetic disorders.
Company News
The Lipid Nanoparticles (LNPs) market is projected to grow from $1 billion in 2024 to $3.5 billion by 2034, driven by increasing demand for mRNA-based therapeutics and advances in drug delivery systems.
The European Commission has approved KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine developed by CSL and Arcturus Therapeutics. KOSTAIVE is the first of its kind to receive approval in Europe and has shown superior immunogenicity and antibody persistence compared to conventional mRNA vaccines.
Arcturus, a leading biotech company, is a top pick in the market with innovative vaccines, strong revenue generation, and promising growth. Read more here.
Gritstone bio (GRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The company saw revenue decline and net losses rise in the second quarter.